Akero Therapeutics Inc
AKRO54.140USD
+0.100+0.19%
Close 11/10, 16:00（ET）Quotes delayed by 15 min
4.34BMarket Cap
LossP/E TTM
More Details of Akero Therapeutics Inc Company
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Akero Therapeutics Inc Info
Ticker SymbolAKRO
Company nameAkero Therapeutics Inc
IPO dateJun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Number of employees63
Security typeOrdinary Share
Fiscal year-endJun 20
Address601 Gateway Boulevard, Suite 350
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16504876488
Websitehttps://akerotx.com/
Ticker SymbolAKRO
IPO dateJun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Company Executives of Akero Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
393.38K
+51.69%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
217.63K
+13.41%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+30.32%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott A. Gangloff
Mr. Scott A. Gangloff
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Judy Chou, Ph.D.
Dr. Judy Chou, Ph.D.
Independent Director
Independent Director
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
393.38K
+51.69%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
217.63K
+13.41%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+30.32%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 3
Updated: Wed, Sep 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
8.19%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.15%
The Vanguard Group, Inc.
5.48%
Other
66.56%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
8.19%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.15%
The Vanguard Group, Inc.
5.48%
Other
66.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
47.16%
Investment Advisor
33.05%
Hedge Fund
22.49%
Private Equity
9.32%
Research Firm
3.22%
Venture Capital
3.01%
Individual Investor
1.29%
Foundation
0.41%
Pension Fund
0.32%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
509
95.38M
115.92%
-917.24K
2025Q2
491
87.62M
109.91%
-627.50K
2025Q1
495
89.01M
111.79%
+1.41M
2024Q4
453
76.50M
96.29%
-13.73M
2024Q3
445
77.37M
111.97%
-14.20M
2024Q2
428
76.12M
110.88%
-16.59M
2024Q1
421
77.80M
117.45%
+1.74M
2023Q4
401
63.49M
113.86%
-5.60M
2023Q3
387
61.40M
112.62%
-2.96M
2023Q2
363
60.44M
111.44%
+4.13M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
6.74M
8.42%
-330.09K
-4.67%
Jun 30, 2025
General Atlantic LLC
5.73M
7.17%
+500.00K
+9.55%
Jun 30, 2025
RTW Investments L.P.
5.48M
6.85%
-1.94M
-26.17%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.06M
6.33%
-421.07K
-7.68%
Jun 30, 2025
The Vanguard Group, Inc.
4.52M
5.65%
+297.51K
+7.05%
Jun 30, 2025
T. Rowe Price Associates, Inc.
4.42M
5.53%
-310.43K
-6.56%
Jun 30, 2025
Deep Track Capital LP
3.04M
3.8%
-167.67K
-5.22%
Jun 30, 2025
Avoro Capital Advisors LLC
3.50M
4.38%
+3.50M
--
Jun 30, 2025
Wellington Management Company, LLP
3.41M
4.26%
-2.53M
-42.56%
Jun 30, 2025
State Street Investment Management (US)
2.75M
3.43%
+250.82K
+10.05%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Simplify Propel Opportunities ETF
10.44%
ALPS Medical Breakthroughs ETF
2.19%
SPDR S&P Biotech ETF
1.64%
AltShares Merger Arbitrage ETF
1.63%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
Virtus LifeSci Biotech Clinical Trials ETF
0.64%
Tema Heart & Health ETF
0.63%
ProShares Ultra Nasdaq Biotechnology
0.39%
Invesco Nasdaq Biotechnology ETF
0.38%
iShares Biotechnology ETF
0.32%
View more
Simplify Propel Opportunities ETF
Proportion10.44%
ALPS Medical Breakthroughs ETF
Proportion2.19%
SPDR S&P Biotech ETF
Proportion1.64%
AltShares Merger Arbitrage ETF
Proportion1.63%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.86%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.64%
Tema Heart & Health ETF
Proportion0.63%
ProShares Ultra Nasdaq Biotechnology
Proportion0.39%
Invesco Nasdaq Biotechnology ETF
Proportion0.38%
iShares Biotechnology ETF
Proportion0.32%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
